Adverse events reported in >10% in any treatment group (safety population)
| Preferred term | Placebo/OL’772* (n=12) | GSK2982772/OL’772† (n=24) |
| Any event (n (%)) | 9 (75) | 18 (75) |
| Headache | 2 (17) | 8 (33) |
| Nasopharyngitis | 1 (8) | 5 (21) |
| Nausea | 2 (17) | 3 (13) |
| Abdominal pain | 0 | 3 (13) |
| Abdominal pain upper | 0 | 3 (13) |
*Placebo/OL’772 patients received placebo until day 43 when all patients switched to open-label GSK2982772 60 mg three times daily.
†GSK2982772/OL’772 patients received GSK2982772 60 mg three times daily until day 43 when all patients switched to open-label GSK2982772 at the same dose.
OL, open-label.